Literature DB >> 3525024

Flow resistance of expiratory positive-pressure valve systems.

M J Banner, S Lampotang, P G Boysen, T E Hurd, D A Desautels.   

Abstract

The flow-resistive characteristics of a variety of commercially available expiratory positive-pressure valve systems used to provide continuous positive airway pressure (CPAP) and positive end-expiratory pressure were evaluated. One flow-resistor and seven threshold-resistor expiratory pressure valve systems were set at 5, 10, 15, 20, and 25 cm H2O of expiratory pressure, and sinusoidal exhaled flows peaking at 50,100, and 200 L/min were directed through each valve at each level of expiratory pressure. The Siemens flow-resistor valve demonstrated the greatest deviation in pressure above set CPAP levels at peak flow rates of 100 and 200 L/min, which suggests high resistance to exhaled flow. The Vital Signs threshold-resistor valve demonstrated the least deviation in pressure from set CPAP levels at all rates of exhaled flow, which suggests low flow resistance. The Emerson and IMV Bird threshold-resistor systems resisted flow less than the BEAR-2 and the Puritan-Bennett MA-2 and 7200 inflatable-balloon threshold-resistor-like valve systems. These data suggest that threshold resistors may be classified as low-resistance or high-resistance types. Using only low-resistance threshold resistors for CPAP may minimize the incidence of barotrauma and other deleterious effects related to airway pressure.

Entities:  

Mesh:

Year:  1986        PMID: 3525024     DOI: 10.1378/chest.90.2.212

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Airway resistance--an old friend re-visited.

Authors:  J J Marini
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

2.  Exhalatory dynamic interactions between patients connected to a shared ventilation device.

Authors:  Pedro M Garcia Eijo; Juan D'Adamo; Arturo Bianchetti; Thomas Duriez; Juan M Cabaleiro; Célica Irrazabal; Pablo Otero; Guillermo Artana
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.